Literature DB >> 17967157

The safety of drugs for the treatment of nausea and vomiting of pregnancy.

Simerpal K Gill1, Adrienne Einarson.   

Abstract

Nausea and vomiting of pregnancy (NVP) is the most common medical condition of pregnancy, affecting up to 80% of all pregnancies to some degree. In most cases it subsides by the week 16 of pregnancy, although up to 20% of women continue to have symptoms throughout pregnancy. Severe NVP (Hyperemesis gravidarum) affects < 1% of women and in some severe cases can require hospitalization and rehydration of fluids. Women suffer not only physically but also psychologically, which has been documented in a number of studies. In addition, some women have decided to terminate their pregnancy rather than tolerate severe symptoms. Even less severe cases of NVP can have significant adverse effects on the quality of a woman's life, affecting her occupational, social, domestic functioning and general well being. Therefore, it is of great importance to treat this condition effectively to improve the quality of life for these women. In this paper, the authors review different classes of antiemetics used to treat this condition and discuss that some have better safety profiles than others, but most appear to be safe to use in pregnancy. Also included is a treatment algorithm that can assist the healthcare provider in treating this condition in pregnant safely and effectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967157     DOI: 10.1517/14740338.6.6.685

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  7 in total

1.  An antiemetic for irritable bowel syndrome?

Authors:  Robert Levy; Jason Corbo; Shailendra Prasad
Journal:  J Fam Pract       Date:  2014-10       Impact factor: 0.493

Review 2.  Antiemetic drugs: what to prescribe and when.

Authors:  Akshay Athavale; Tegan Athavale; Darren M Roberts
Journal:  Aust Prescr       Date:  2020-04-01

3.  Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.

Authors:  Marlene Anderka; Allen A Mitchell; Carol Louik; Martha M Werler; Sonia Hernández-Diaz; Sonja A Rasmussen
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-11-19

4.  Review of NVP and HG and Early Pharmacotherapeutic Intervention.

Authors:  Shannon M Clark; Maged M Costantine; Gary D V Hankins
Journal:  Obstet Gynecol Int       Date:  2011-11-24

5.  Italian guidelines for primary headaches: 2012 revised version.

Authors:  Paola Sarchielli; Franco Granella; Maria Pia Prudenzano; Luigi Alberto Pini; Vincenzo Guidetti; Giorgio Bono; Lorenzo Pinessi; Massimo Alessandri; Fabio Antonaci; Marcello Fanciullacci; Anna Ferrari; Mario Guazzelli; Giuseppe Nappi; Grazia Sances; Giorgio Sandrini; Lidia Savi; Cristina Tassorelli; Giorgio Zanchin
Journal:  J Headache Pain       Date:  2012-05       Impact factor: 7.277

Review 6.  The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy.

Authors:  Svetlana Madjunkova; Caroline Maltepe; Gideon Koren
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

Review 7.  Preventing nausea and vomiting in women undergoing regional anesthesia for cesarean section: challenges and solutions.

Authors:  Yvonne Jelting; Christian Klein; Thomas Harlander; Leopold Eberhart; Norbert Roewer; Peter Kranke
Journal:  Local Reg Anesth       Date:  2017-08-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.